Lifecore Biomedical, Inc.
LFCR · Price history
Price at last available close
$6.44
−$0.08 (-1.23%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Lifecore Biomedical, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications.
How they make money
Lifecore Biomedical operates as a contract development and manufacturing organization (CDMO) that provides specialized aseptic fill and finish services for complex injectable pharmaceutical products. The company generates revenue by entering into long-term manufacturing agreements with pharmaceutical and biotechnology companies, charging fees for development, clinical trial support, and commercial-scale cGMP manufacturing of drug products.
Products & services
Lifecore provides contract development and manufacturing services, including formulation development, aseptic fill and finish, and regulatory support for complex injectable drug products.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company discloses that it has significant customer concentration, where a limited number of customers account for a substantial portion of its total revenue for the period ended December 31, 2025.
Suppliers, materials & equipment
- Raw material and component suppliers — The company relies on various third-party suppliers for raw materials, active pharmaceutical ingredients, and packaging components required for its manufacturing processes.Source
Strengths
- Multi-compendial quality and regulatory system with a long track record of compliance with global regulatory bodies like the FDA and EMA.Source
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
12
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
13
Poor
Financial Strength
15
Business Quality / Moat
0
Management
25
Growth Quality
14
Risk / Durability
10
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
23
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
26/100
Building Historical Record
Model Score 26/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •Severe debt stress
- •M&A headline · Sep 29, 2026
- •M&A headline · Sep 28, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for LFCR
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving LFCR's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is LFCR's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is LFCR's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for LFCR to reach sustainable profitability?
- •What future growth or profitability would be needed to justify LFCR's current valuation?
Essential Investment Snapshot
Wall Street Score
12
Opportunity Score
23
Market Cap
$244.1M
P/E Ratio
-5.9
EPS
$-1.10
52-Week High
$8.98
52-Week Low
$3.63
Beta
1.08
Analyst Target
$6.39
Shares Outstanding
37.4M
Total Revenue
$122.6M
Total Debt
$155.1M
Dividend
No current dividend
Liquidation Value / Share
$-0.91
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for LFCR
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Severe debt stress
Negative shareholder equity • Total debt is at least one year of revenue • Interest coverage is below 2x • Cash covers less than 20% of total debt
M&A headline · Sep 29, 2026
Lifecore agrees to acquisition with CVRs up to $160 million — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldM&A headline · Sep 28, 2026
LFCR SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES LIFECORE BIOMEDICAL, INC. — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
PRNewsWireM&A headline · Sep 28, 2026
Lifecore Biomedical to be Acquired by Webster Equity Partners — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on LFCR.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Multi-compendial quality and regulatory system with a long track record of compliance with global regulatory bodies like the FDA and EMA.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Debt risk (severe): Negative shareholder equity.
- −Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Cash covers less than 20% of total debt.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
14
Jul 24, 2026
Change
-2.1
points
Current Score
12
Oct 1, 2026
Category Changes
LFCR decreased 2.1 points because Debt declined by 28.4 points, Revenue declined by 7.5 points, Asset declined by 4.8 points.
Positive Contributors
- + Management improved by 25 points
Negative Contributors
- − Debt declined by 28.4 points
- − Revenue declined by 7.5 points
- − Asset declined by 4.8 points
- − Buffett declined by 5.5 points
Projected Score
Projected Score
11
Projected Change
-1.3 points
Preliminary comparable-period financial changes suggest decline of approximately 1.3 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$6.44
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $135.9M | $129.5M | $128.9M | $128.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $91.4M | $88.9M | $88.6M | $86.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $44.5M | $40.6M | $40.3M | $41.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $6.6M | $8.5M | $8.3M | $8.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $31.4M | $33.4M | $44.0M | $40.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $41.7M | $41.9M | $57.5M | $50.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $8.0M | $8.2M | -$8.8M | $35.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $2.8M | -$1.3M | -$17.2M | -$8.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $32.3M | -$2.2M | $21.8M | $18.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$35.2M | -$30.2M | -$38.7M | $9.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $93K | $578K | $43K | $183K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$35.3M | -$30.8M | -$38.7M | $12.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.06 | $-0.92 | $-1.27 | $0.39 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 37.57M | 33.26M | 34.82M | 30.47M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 37.57M | 37.37M | 34.82M | 36.66M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$34.2M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.19
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+18.5%
Cash Change
+108.6%
Margin Change
-14.9 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included EPS growth, cash levels. Pressure indicators included revenue growth, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 6.2%. EPS increased 243.6%. Cash increased 108.6%. Total debt increased 18.5%. Net income margin declined by 14.9 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericNews
Halper Sadeh LLC is Investigating Whether LFCR and SSTI are Obtaining Fair Deals for their Shareholders
Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCR
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capital Bancorp, Inc. (Nasdaq – CBNK), Lifecore Biomedical, Inc. (Nasdaq – LFCR), MISTRAS Group, Inc. (NYSE – MG), Utz Brands, Inc. (NYSE – UTZ)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)
Rumor Mill · LFCR
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial